Who is Burna AI for?

Burna AI serves three primary buyer segments in oncology drug safety. First, Clinical Research Directors at NCI-designated cancer centers and academic medical centers managing 50 to 100+ active oncology trials. Second, CRO and Phase 1 site operators managing multi-site oncology trials where query reduction, EDC write-back, and cross-site visibility are immediate pain points. Third, VP Clinical Development, Head of Patient Safety, and Director of Pharmacovigilance at pharma and biotech sponsors that need protocol-aware attribution during trials and postmarket adverse event processing on approved drugs.